Literature DB >> 20435883

SOCS3 regulates graft-versus-host disease.

Geoffrey R Hill1, Rachel D Kuns, Neil C Raffelt, Alistair L J Don, Stuart D Olver, Kate A Markey, Yana A Wilson, Joel Tocker, Warren S Alexander, Andrew D Clouston, Andrew W Roberts, Kelli P A MacDonald.   

Abstract

Suppressor of cytokine signaling-3 (SOCS3) is the main intracellular regulator of signaling by granulocyte colony-stimulating factor, an immune-modulatory cytokine used to mobilize stem cells for transplantation. We have therefore studied the contribution of SOCS3 to the spectrum of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (SCT). Grafts from SOCS3(-/Deltavav) donor mice in which SOCS3 deficiency is restricted to the hematopoietic compartment had an augmented capacity to induce acute GVHD. With the use of SOCS3(-/DeltaLysM) and SOCS3(-/Deltalck) donors in which SOCS3 deficiency was restricted to the myeloid or T-cell lineage, respectively, we confirmed SOCS3 deficiency promoted acute GVHD mortality and histopathology within the gastrointestinal tract by effects solely within the donor T cell. SOCS3(-/Deltalck) donor T cells underwent enhanced alloantigen-dependent proliferation and generation of interleukin-10 (IL-10), IL-17, and interferon-gamma (IFNgamma) after SCT. The enhanced capacity of the SOCS3(-/Deltalck) donor T cell to induce acute GVHD was dependent on IFNgamma but independent of IL-10 or IL-17. Surprisingly, SOCS3(-/Deltalck) donor T cells also induced severe, transforming growth factor beta- and IFNgamma-dependent, sclerodermatous GVHD. Thus, the delivery of small molecule SOCS3 mimetics may prove to be useful for the inhibition of both acute and chronic GVHD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20435883      PMCID: PMC2910612          DOI: 10.1182/blood-2009-12-259598

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma.

Authors:  Geoffrey R Hill; Stuart D Olver; Rachel D Kuns; Antiopi Varelias; Neil C Raffelt; Alistair L Don; Kate A Markey; Yana A Wilson; Mark J Smyth; Yoichiro Iwakura; Joel Tocker; Andrew D Clouston; Kelli P A Macdonald
Journal:  Blood       Date:  2010-04-30       Impact factor: 22.113

2.  Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance.

Authors:  Charles E Egwuagu; Cheng-Rong Yu; Meifen Zhang; Rashid M Mahdi; Stephen J Kim; Igal Gery
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

Review 3.  Advances in the understanding of acute graft-versus-host disease.

Authors:  Edward S Morris; Geoffrey R Hill
Journal:  Br J Haematol       Date:  2007-04       Impact factor: 6.998

4.  SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor beta2 subunit.

Authors:  Koh Yamamoto; Mitsuko Yamaguchi; Nobuyuki Miyasaka; Osamu Miura
Journal:  Biochem Biophys Res Commun       Date:  2003-10-31       Impact factor: 3.575

5.  Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction.

Authors:  Michael Hörtner; Ulrich Nielsch; Lorenz M Mayr; James A Johnston; Peter C Heinrich; Serge Haan
Journal:  J Immunol       Date:  2002-08-01       Impact factor: 5.422

6.  SOCS3 negatively regulates IL-6 signaling in vivo.

Authors:  Ben A Croker; Danielle L Krebs; Jian-Guo Zhang; Sam Wormald; Tracy A Willson; Edouard G Stanley; Lorraine Robb; Christopher J Greenhalgh; Irmgard Förster; Björn E Clausen; Nicos A Nicola; Donald Metcalf; Douglas J Hilton; Andrew W Roberts; Warren S Alexander
Journal:  Nat Immunol       Date:  2003-05-18       Impact factor: 25.606

7.  IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages.

Authors:  Hideo Yasukawa; Masanobu Ohishi; Hiroyuki Mori; Masaaki Murakami; Takatoshi Chinen; Daisuke Aki; Toshikatsu Hanada; Kiyoshi Takeda; Shizuo Akira; Masahiko Hoshijima; Toshio Hirano; Kenneth R Chien; Akihiko Yoshimura
Journal:  Nat Immunol       Date:  2003-05-18       Impact factor: 25.606

8.  IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract.

Authors:  Angela C Burman; Tatjana Banovic; Rachel D Kuns; Andrew D Clouston; Amanda C Stanley; Edward S Morris; Vanessa Rowe; Helen Bofinger; Renae Skoczylas; Neil Raffelt; Olivier Fahy; Shaun R McColl; Christian R Engwerda; Kelli P A McDonald; Geoffrey R Hill
Journal:  Blood       Date:  2007-04-20       Impact factor: 22.113

9.  Deficient SOCS3 expression in CD4+CD25+FoxP3+ regulatory T cells and SOCS3-mediated suppression of Treg function.

Authors:  Brendan B L Pillemer; Hui Xu; Timothy B Oriss; Zengbiao Qi; Anuradha Ray
Journal:  Eur J Immunol       Date:  2007-08       Impact factor: 5.532

10.  Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Kelli P A MacDonald; Vanessa Rowe; Cheryl Filippich; Ranjeny Thomas; Andrew D Clouston; Joseph K Welply; Derek N J Hart; James L M Ferrara; Geoffrey R Hill
Journal:  Blood       Date:  2002-10-17       Impact factor: 22.113

View more
  19 in total

1.  Smg1 haploinsufficiency predisposes to tumor formation and inflammation.

Authors:  Tara L Roberts; Uda Ho; John Luff; C Soon Lee; Simon H Apte; Kelli P A MacDonald; Liza J Raggat; Allison R Pettit; Carl A Morrow; Michael J Waters; Phil Chen; Rick G Woods; Gethin P Thomas; Liam St Pierre; Camile S Farah; Raymond A Clarke; James A L Brown; Martin F Lavin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-31       Impact factor: 11.205

2.  SOCS3 overexpression in T cells ameliorates chronic airway obstruction in a murine heterotopic tracheal transplantation model.

Authors:  Kumi Mesaki; Masaomi Yamane; Seiichiro Sugimoto; Masayoshi Fujisawa; Teizo Yoshimura; Takeshi Kurosaki; Shinji Otani; Shinichiro Miyoshi; Takahiro Oto; Akihiro Matsukawa; Shinichi Toyooka
Journal:  Surg Today       Date:  2019-01-07       Impact factor: 2.549

Review 3.  The IL-17 differentiation pathway and its role in transplant outcome.

Authors:  Jonathan S Serody; Geoffrey R Hill
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

4.  Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein.

Authors:  Steven O'Reilly; Marzena Ciechomska; Rachel Cant; Jacob M van Laar
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

5.  Microsatellite scanning of the immunogenome associates MAPK14 and ELTD1 with graft-versus-host disease in hematopoietic stem cell transplantation.

Authors:  Christian Harkensee; Akira Oka; Makoto Onizuka; Peter G Middleton; Hidetoshi Inoko; Hirofumi Nakaoka; Andrew R Gennery; Kiyoshi Ando; Yasuo Morishima
Journal:  Immunogenetics       Date:  2013-03-09       Impact factor: 2.846

6.  The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics.

Authors:  Marina G M Castor; Vanessa Pinho; Mauro M Teixeira
Journal:  Front Pharmacol       Date:  2012-02-24       Impact factor: 5.810

7.  Critical and independent role for SOCS3 in either myeloid or T cells in resistance to Mycobacterium tuberculosis.

Authors:  Berit Carow; Ann-Kathrin Reuschl; Dolores Gavier-Widén; Brendan J Jenkins; Matthias Ernst; Akihiko Yoshimura; Benedict J Chambers; Martin E Rottenberg
Journal:  PLoS Pathog       Date:  2013-07-04       Impact factor: 6.823

Review 8.  SOCS3, a Major Regulator of Infection and Inflammation.

Authors:  Berit Carow; Martin E Rottenberg
Journal:  Front Immunol       Date:  2014-02-19       Impact factor: 7.561

9.  Expression of SOCS1 and SOCS3 genes in human graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Tae Hyang Lee; Ji Yoon Lee; Sohye Park; Seung Hwan Shin; Seung-Ah Yahng; Jae-Ho Yoon; Sung-Eun Lee; Byung-Sik Cho; Yoo-Jin Kim; Seok Lee; Chang-Ki Min; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Chong-Won Park; Hee-Je Kim
Journal:  Blood Res       Date:  2013-03-25

Review 10.  Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis.

Authors:  Leslie S Kean
Journal:  Blood       Date:  2018-05-04       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.